Salivary gland dosimetry in therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617

被引：0
|
作者：
Happel, C. [1 ]
Voeller, L. [1 ]
Kranert, W. T. [1 ]
Baumgarten, J. [1 ]
Groener, D. [1 ]
Gruenwald, F. [1 ]
Sabet, A. [1 ]
机构：
[1] Univ Med Ctr Frankfurt, Dept Nucl Med, Frankfurt, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPS-035
引用
收藏
页码：S102 / S102
页数：1
相关论文
共 50 条
  • [1] Hematotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Zimbelmann, Stefanie
    Eppard, Elisabeth
    Hauser, Stefan
    Kuerpig, Stefan
    Yordanova, Anna
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [2] Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
    Ferdinandus, Justin
    Eppard, Elisabeth
    Gaertner, Florian C.
    Kuerpig, Stefan
    Fimmers, Rolf
    Yordanova, Anna
    Hauser, Stefan
    Feldmann, Georg
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (02) : 312 - 319
  • [3] Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Ferdinandus, Justin
    Eppard, Elisabeth
    Kuerpig, Stefan
    Gaertner, Florian
    Fimmers, Rolf
    Hauser, Stefan
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [4] Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Ferdinandus, J.
    Eppard, E.
    Kuerpig, S.
    Gaertner, F.
    Fimmers, R.
    Yordanova, A.
    Hauser, S.
    Essler, M.
    Feldmann, G.
    Ahmadzadehfar, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S212 - S213
  • [5] Nephro- and hepatotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Becker, Anja
    Eppard, Elisabeth
    Kuerpig, Stefan
    Fisang, Christian
    Yordanova, Anna
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [6] Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC).
    Rami, Avina
    Ng, Thomas S. C.
    Rothmann, Emily
    Stoltenberg, Hailey
    Wolanski, Andrew
    Ritzer, Jolivette
    Choudhury, Atish Dipankar
    Gao, Xin
    Haberman, Veronica
    Kako, Bashar
    Kilbridge, Kerry L.
    Morgans, Alicia K.
    O'Shea, Aileen
    Taplin, Mary-Ellen
    Jacene, Heather
    Ravi, Praful
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 27 - 27
  • [7] EVALUATION OF RESPONSE TO 177LU-PSMA-617 BY SITE SPECIFIC DISEASE IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER
    Mahmoud, Ahmed M.
    Ahmed, Mohamed E.
    Abdelrazek, Ahmad
    Childs, Daniel
    Kendi, Ayse T.
    Johnson, Geoffrey
    Karnes, Jeffrey
    Kwon, Eugene
    Andrews, Jack
    JOURNAL OF UROLOGY, 2024, 211 (05): : E1004 - E1004
  • [8] EVALUATION OF RESPONSE TO 177LU-PSMA-617 BY SITE SPECIFIC DISEASE IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER
    Mohamed, E. Ahmed
    Giuseppe, Reitano
    Ahmed, Mahmoud
    Umar, Ghaffar
    Tuba, Kendi Ayse
    Jeffrey, Karnes R.
    Eugene, Kwon
    Jack, Andrews
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [9] Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis
    Kim, Yong Joong
    Kim, Yong-il
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (10) : 728 - 734
  • [10] RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.
    Calais, Jeremie
    Fendler, Wolfgang P.
    Eiber, Matthias
    Lassmann, MIchael
    Dahlbom, Magnus
    Esfandiari, Rouzbeh
    Gartmann, Jeannine
    Nguyen, Kathleen
    Pan Thin
    Lok, Vincent
    Herrmann, Ken
    Czernin, Johannes
    Delpassand, Ebrahim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345